Azapiron

Azapironi su klasa lekova koji se koriste kao anksiolitici i antipsihotici.^[1]^[2]^[3]^[4] Oni se isto tako koriste kao zamena za antidepresive poput selektivnih inhibitora preuzimanja serotonina (SSRI).^[5]^[6]^[7]^[8]^[9]

Reference

^ Eison AS (1990). „Azapirones: history of development”. Journal of Clinical Psychopharmacology. 10 (3 Suppl): 2S—5S. PMID 1973936.
^ Cadieux RJ (1996). „Azapirones: an alternative to benzodiazepines for anxiety”. American Family Physician. 53 (7): 2349—53. PMID 8638511.
^ Chessick CA, Allen MH, Thase M (2006). Chessick CA, ур. „Azapirones for generalized anxiety disorder”. Cochrane Database of Systematic Reviews (Online). 3: CD006115. PMID 16856115. doi:10.1002/14651858.CD006115.
^ Feighner JP, Boyer WF (1989). „Serotonin-1A anxiolytics: an overview”. Psychopathology. 22 Suppl 1: 21—6. PMID 2567039.
^ Van Ameringen M, Mancini C, Wilson C (1996). „Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia”. Journal of Affective Disorders. 39 (2): 115—21. PMID 8827420. doi:10.1016/0165-0327(96)00030-4.
^ Bouwer C, Stein DJ (1997). „Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression”. South African Medical Journal. 87 (4 Suppl): 534—7, 540. PMID 9180827.
^ Dimitriou EC, Dimitriou CE (1998). „Buspirone augmentation of antidepressant therapy”. Journal of Clinical Psychopharmacology. 18 (6): 465—9. PMID 9864079. doi:10.1097/00004714-199812000-00009.
^ Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH (2001). „Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study”. The Journal of Clinical Psychiatry. 62 (6): 448—52. PMID 11465522. doi:10.4088/JCP.v62n0608.
^ Yamada K, Yagi G, Kanba S (2003). „Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial”. Psychiatry and Clinical Neurosciences. 57 (2): 183—7. PMID 12667165. doi:10.1046/j.1440-1819.2003.01099.x. ^{[мртва веза]}

[pmid1973936-1] Eison AS (1990). „Azapirones: history of development”. Journal of Clinical Psychopharmacology. 10 (3 Suppl): 2S—5S. PMID 1973936.

[pmid8638511-2] Cadieux RJ (1996). „Azapirones: an alternative to benzodiazepines for anxiety”. American Family Physician. 53 (7): 2349—53. PMID 8638511.

[pmid16856115-3] Chessick CA, Allen MH, Thase M (2006). Chessick CA, ур. „Azapirones for generalized anxiety disorder”. Cochrane Database of Systematic Reviews (Online). 3: CD006115. PMID 16856115. doi:10.1002/14651858.CD006115.

[pmid2567039-4] Feighner JP, Boyer WF (1989). „Serotonin-1A anxiolytics: an overview”. Psychopathology. 22 Suppl 1: 21—6. PMID 2567039.

[pmid8827420-5] Van Ameringen M, Mancini C, Wilson C (1996). „Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia”. Journal of Affective Disorders. 39 (2): 115—21. PMID 8827420. doi:10.1016/0165-0327(96)00030-4.

[pmid9180827-6] Bouwer C, Stein DJ (1997). „Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression”. South African Medical Journal. 87 (4 Suppl): 534—7, 540. PMID 9180827.

[pmid9864079-7] Dimitriou EC, Dimitriou CE (1998). „Buspirone augmentation of antidepressant therapy”. Journal of Clinical Psychopharmacology. 18 (6): 465—9. PMID 9864079. doi:10.1097/00004714-199812000-00009.

[pmid11465522-8] Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH (2001). „Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study”. The Journal of Clinical Psychiatry. 62 (6): 448—52. PMID 11465522. doi:10.4088/JCP.v62n0608.

[pmid12667165-9] Yamada K, Yagi G, Kanba S (2003). „Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial”. Psychiatry and Clinical Neurosciences. 57 (2): 183—7. PMID 12667165. doi:10.1046/j.1440-1819.2003.01099.x. ^{[мртва веза]}

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]